The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.
 
Pavlina Spiliopoulou
Honoraria - Pfizer
 
Ashley Rooney
No Relationships to Disclose
 
Sofia Genta
No Relationships to Disclose
 
Maria Kulikova
No Relationships to Disclose
 
Ben X Wang
Honoraria - AstraZeneca; Tessa Therapeutics
Consulting or Advisory Role - Providence Therapeutics
 
Ming Sound Tsao
Honoraria - Sanofi/Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly
Speakers' Bureau - Abbvie; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Sanofi (Inst)
 
Sam Felicen
No Relationships to Disclose
 
Vanessa Speers
No Relationships to Disclose
 
Theresa Patrick
No Relationships to Disclose
 
Alisa Nguyen
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Lawson Eng
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Sam Saibil
Honoraria - Janssen; Novartis Biociencias
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Trevor John Pugh
Honoraria - AstraZeneca; Illumina; Merck; PACT Pharma
Consulting or Advisory Role - Axiom Healthcare Strategies; Chrysalis Biomedical Advisors; SAGA Diagnostics
Research Funding - Roche
Patents, Royalties, Other Intellectual Property - Hybrid-capture sequencing for dete rmining immune cell clonality
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Bryan Coburn
Research Funding - Nubiyota (Inst); Sanofi (Inst)
 
Anna Spreafico
Honoraria - Immunocore; Medison
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Medison; Merck
Research Funding - Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Treadwell Therapeutics (Inst)